Biologic therapy of liver tumors

Surgical Clinics of North America

Volumn 84, Issue 2, 2004, Pages 673-696

  Prieto, Jesus ^a   Qian, Cheng ^a   Sangro, Bruno ^a   Melero, Ignacio ^a   Mazzolini, Guillermo ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANGIOSTATIN; ANTISENSE OLIGONUCLEOTIDE; BCG VACCINE; BEVACIZUMAB; CETUXIMAB; EDRECOLOMAB; ENDOSTATIN; FLUTAMIDE; GASTRIMMUNE; GEFITINIB; HORMONE DERIVATIVE; MEGESTROL ACETATE; MONOCLONAL ANTIBODY LM 609; OCTREOTIDE; PICIBANIL; POLYPRENOIC ACID; RETINOIC ACID DERIVATIVE; RETINOID; SOMATOSTATIN DERIVATIVE; TAMOXIFEN; THROMBOSPONDIN; THYMOSIN; TRIPTORELIN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANGIOGENESIS; CANCER HORMONE THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CELL ADHESION; CELL CYCLE PHASE; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DNA SEQUENCE; GENE THERAPY; HUMAN; LIVER CARCINOGENESIS; LIVER TUMOR; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT FAILURE;

ADENOVIRIDAE; ANIMALS; BIOLOGICAL RESPONSE MODIFIERS; CANCER VACCINES; DENDRITIC CELLS; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-ALPHA; LIVER; LIVER NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 1642401096     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(03)00230-5     Document Type: Review

References (117)

1. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 35:2001;421-430.
2. Lorenz M., Staib-Sebler E., Hochmuth K., Heinrich S., Gog C., Vetter G., et al. Surgical resection of liver metastases of colorectal carcinoma: short and long-term results. Semin Oncol. 27:2000;112-119.
3. Saltz L.B., Douillard J.Y., Pirotta N., Alakl M., Gruia G., Awad L., et al. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist. 6:2001;81-91.
4. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 18:2000;2938-2947.
5. Bismuth H., Adam R. Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy. Semin Oncol. 25:1998;40-46.
6. Manesis E.K., Giannoulis G., Zoumboulis P., Vafiadou I., Hadziyannis S.J. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology. 21:1995;1535-1542.
7. Chao Y., Chan W.K., Wang S.S., Lai K.H., Chi C.W., Lin C.Y., et al. Phase II study of megestrol acetate in the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 12:1997;277-281.
8. Villa E., Ferretti I., Grottola A., Buttafoco P., Buono M.G., Giannini F., et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer. 84:2001;881-885.
9. Reubi J.C., Zimmermann A., Jonas S., Waser B., Neuhaus P., Laderach U., et al. Regulatory peptide receptors in human hepatocellular carcinomas. Gut. 45:1999;766-774.
10. Woodburn J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. 82:1999;241-250.
11. O'Dwyer P.J., Benson A.B. 3rd. Epidermal growth factor receptor-targeted therapy in colorectal cancer. Semin Oncol. 29:2002;10-17.
12. Baselga J., Rischin D., Ranson M., Calvert H., Raymond E., Kieback D.G., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 20:2002;4292-4302.
13. Marill J., Idres N., Capron C.C., Nguyen E., Chabot G.G. Retinoic acid metabolism and mechanism of action: a review. Curr Drug Metab. 4:2003;1-10.
14. Bollag W., Holdener E.E. Retinoids in cancer prevention and therapy. Ann Oncol. 3:1992;513-526.
15. Muto Y., Moriwaki H., Ninomiya M., Adachi S., Saito A., Takasaki K.T., et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepato cellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med. 334:1996;1561-1567.
16. Meyskens F.L. Jr., Jacobson J., Nguyen B., Weiss G.R., Gandara D.R., MacDonald J.S. Phase II trial of oral beta-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157). Invest New Drugs. 16:1998;171-173.
17. Smith A.M., Justin T., Michaeli D., Watson S.A. Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer. Clin Cancer Res. 6:2000;4719-4724.
18. Brett B.T., Smith S.C., Bouvier C.V., Michaeli D., Hochhauser D., Davidson B.R., et al. Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol. 20:2002;4225-4231.
19. Punt C.J., Nagy A., Douillard J.Y., Figer A., Skovsgaard T., Monson J., et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet. 360:2002;671-677.
20. Order SE, Klein JL, Leichner PK. Hepatoma: model for radiolabeled antibody in cancer treatment, NCI Monogr 7-4., 1987.
21. Stillwagon G.B., Order S.E., Klein J.L., Leichner P.K., Leibel S.A., Siegelman S.S., et al. Multi-modality treatment of primary nonresectable intrahepatic cholangiocarcinoma with 131I anti-CEA - a Radiation Therapy Oncology Group Study. Int J Radiat Oncol Biol Phys. 13:1987;687-695.
22. Divgi C.R., Scott A.M., Gulec S., Broussard E.K., Levy N., Young C., et al. Pilot radioimmunotherapy trial with 131I-labeled murine monoclonal antibody CC49 and deoxyspergualin in metastatic colon carcinoma. Clin Cancer Res. 1:1995;1503-1510.
23. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2:2002;727-739.
24. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:1995;27-31.
25. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
26. Kandel J., Bossy-Wetzel E., Radvanyi F., Klagsbrun M., Folkman J., Hanahan D. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell. 66:1991;1095-1104.
27. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:1997;277-285.
28. Eder J.P. Jr., Supko J.G., Clark J.W., Puchalski T.A., Garcia-Carbonero R., Ryan D.P., et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol. 20:2002;3772-3784.
29. Yang J.C., Haworth L., Steinberg S.M., Rosenberg S.A., Novotny W. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 349:2003;427-434.
30. Jayson G.C., Zweit J., Jackson A., Mulatero C., Julyan P., Ranson M., et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst. 94:2002;1484-1493.
31. Gutheil J.C., Campbell T.N., Pierce P.R., Watkins J.D., Huse W.D., Bodkin D.J., et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res. 6:2000;3056-3061.
32. Singh R.K., Gutman M., Bucana C.D., Sanchez R., Llansa N., Fidler I.J. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A. 92:1995;4562-4566.
33. Hirata A., Ogawa S., Kometani T., Kuwano T., Naito S., Kuwano M., et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res. 62:2002;2554-2560.
34. Colleoni M., Buzzoni R., Bajetta E., Bochicchio A.M., Bartoli C., Audisio R., et al. A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma. Cancer. 72:1993;3196-3201.
35. Forbes A., Johnson P.J., Williams R. Recombinant human gamma-interferon in primary hepatocellular carcinoma. J R Soc Med. 78:1985;826-829.
36. Lai C.L., Lau J.Y., Wu P.C., Ngan H., Chung H.T., Mitchell S.J., et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology. 17:1993;389-394.
37. Llovet J.M., Sala M., Castells L., Suarez Y., Vilana R., Bianchi L., et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology. 31:2000;54-58.
38. Kubo S., Nishiguchi S., Hirohashi K., Tanaka H., Shuto T., Yamazaki O., et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med. 134:2001;963-967.
39. Ikeda K., Arase Y., Saitoh S., Kobayashi M., Suzuki Y., Suzuki F., et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology. 32:2000;228-232.
40. Shiratori Y., Shiina S., Teratani T., Imamura M., Obi S., Sato S., et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med. 138:2003;299-306.
41. Patt Y.Z., Hassan M.M., Lozano R.D., Brown T.D., Vauthey J.N., Curley S.A., et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol. 21:2003;421-427.
42. Sakon M., Nagano H., Dono K., Nakamori S., Umeshita K., Yamada A., et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer. 94:2002;435-442.
43. Grem J.L., Jordan E., Robson M.E., Binder R.A., Hamilton J.M., Steinberg S.M., et al. Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma. J Clin Oncol. 11:1993;1737-1745.
44. Hausmaninger H., Moser R., Samonigg H., Mlineritsch B., Schmidt H., Pecherstorfer M., et al. Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study. Eur J Cancer. 35:1999;380-385.
45. Fountzilas G., Zisiadis A., Dafni U., Konstantaras C., Hatzitheoharis G., Papavramidis S., et al. Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Oncology. 58:2000;227-236.
46. Jo M., Kim T.H., Seol D.W., Esplen J.E., Dorko K., Billiar T.R., et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med. 6:2000;564-567.
47. Palmieri G., Montella L., Milo M., Fiore R., Biondi E., Bianco A.R., et al. Ultra-low-dose interleukin-2 in unresectable hepatocellular carcinoma. Am J Clin Oncol. 25:2002;224-226.
48. Aldeghi R., Lissoni P., Barni S., Ardizzoia A., Tancini G., Piperno A., et al. Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma. Eur J Cancer. 30A:1994;167-170.
49. Ishikawa T., Imawari M., Moriyama T., Ohnishi S., Matsuhashi N., Suzuki G., et al. Immunotherapy of hepatocellular carcinoma with autologous lymphokine-activated killer cells and/or recombinant interleukin-2. J Cancer Res Clin Oncol. 114:1988;283-290.
50. Patt Y.Z., Mavligit G.M. Arterial chemotherapy in the management of colorectal cancer: an overview. Semin Oncol. 18:1991;478-490.
51. Okuno K., Hirohata T., Nakamura K., Jinnai H., Shigeoka H., Koh K., et al. Hepatic arterial infusions of interleukin-2-based immunochemotherapy in the treatment of unresectable liver metastases from colorectal cancer. Clin Ther. 15:1993;672-683.
52. Lygidakis N.J., Savanis G., Pothoulakis J., Kapetanakis A. Transarterial locoregional immunostimulation and chemotherapy in patients with unresectable secondary liver tumours. Anticancer Res. 14:1994;643-646.
53. Kuhns M.S., Epshteyn V., Sobel R.A., Allison J.P. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4 + T cells. Proc Natl Acad Sci U S A. 97:2000;12711-12716.
54. Todryk S.M., Tutt A.L., Green M.H., Smallwood J.A., Halanek N., Dalgleish A.G., et al. CD40 ligation for immunotherapy of solid tumours. J Immunol Methods. 248:2001;139-147.
55. Melero I., Shuford W.W., Newby S.A., Aruffo A., Ledbetter J.A., Hellstrom K.E., et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 3:1997;682-685.
56. Melero I., Gabari I., Corbi A.L., Relloso M., Mazzolini G., Schmitz V., et al. An anti-ICAM-2 (CD102) monoclonal antibody induces immune-mediated regressions of transplanted ICAM-2-negative colon carcinomas. Cancer Res. 62:2002;3167-3174.
57. Pardoll D.M. Therapeutic vaccination for cancer. Clin Immunol. 95:2000;S44-S62.
58. Stift A., Friedl J., Dubsky P., Bachleitner-Hofmann T., Schueller G., Zontsich T., et al. Dendritic cell-based vaccination in solid cancer. J Clin Oncol. 21:2003;135-142.
59. Nair S.K., Morse M., Boczkowski D., Cumming R.I., Vasovic L., Gilboa E., et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg. 235:2002;540-549.
60. Takayama T., Sekine T., Makuuchi M., Yamasaki S., Kosuge T., Yamamoto J., et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 356:2000;802-807.
61. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:2002;850-854.
62. Kono K., Takahashi A., Ichihara F., Amemiya H., Iizuka H., Fujii H., et al. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res. 8:2002;1767-1771.
63. Mulligan R.C. The basic science of gene therapy. Science. 260:1993;926-932.
64. Miller A.D. Human gene therapy comes of age. Nature. 357:1992;455-460.
65. Lotze M.T., Kost T.A. Viruses as gene delivery vectors: application to gene function, target validation, and assay development. Cancer Gene Ther. 9:2002;692-699.
66. Davis M.E. Non-viral gene delivery systems. Curr Opin Biotechnol. 13:2002;128-131.
67. Ruiz J., Mazzolini G., Sangro B., Qian C., Prieto J. Gene therapy of hepatocellular carcinoma. Dig Dis. 19:2001;324-332.
68. Saleh M., Stacker S.A., Wilks A.F. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res. 56:1996;393-401.
69. Goldman C.K., Kendall R.L., Cabrera G., Soroceanu L., Heike Y., Gillespie G.Y., et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci U S A. 95:1998;8795-8800.
70. Lin P., Buxton J.A., Acheson A., Radziejewski C., Maisonpierre P.C., Yancopoulos G.D., et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci U S A. 95:1998;8829-8834.
71. O'Reilly M.S., Holmgren L., Chen C., Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 2:1996;689-692.
72. Griscelli F., Li H., Bennaceur-Griscelli A., Soria J., Opolon P., Soria C., et al. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci U SA. 95:1998;6367-6372.
73. Schmitz V., Wang L., Barajas M., Peng D., Prieto J., Qian C. A novel strategy for the generation of angiostatic kringle regions from a precursor derived from plasminogen. Gene Ther. 9:2002;1600-1606.
74. Kuo C.J., Farnebo F., Yu E.Y., Christofferson R., Swearingen R.A., Carter R., et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci U S A. 98:2001;4605-4610.
75. Fillat C., Carrio M., Cascante A., Sangro B. Suicide gene therapy mediated by the Herpes simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr Gene Ther. 3:2003;13-26.
76. Mesnil M., Yamasaki H. Bystander effect in Herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res. 60:2000;3989-3999.
77. Kianmanesh A.R., Perrin H., Panis Y., Fabre M., Nagy H.J., Houssin D., et al. A "distant bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. Hum Gene Ther. 8:1997;1807-1814.
78. Drozdzik M., Qian C., Xie X., Peng D., Bilbao R., Mazzolini G., et al. Combined gene therapy with suicide gene and interleukin-12 is more efficient than therapy with one gene alone in a murine model of hepatocellular carcinoma. J Hepatol. 32:2000;279-286.
79. Bilbao R., Gerolami R., Bralet M.P., Qian C., Tran P.L., Tennant B., et al. Transduction efficacy, antitumoral effect, and toxicity of adenovirus-mediated herpes simplex virus thymidine kinase/ ganciclovir therapy of hepatocellular carcinoma: the woodchuck animal model. Cancer Gene Ther. 7:2000;657-662.
80. Qian C., Idoate M., Bilbao R., Sangro B., Bruna O., Vazquez J., et al. Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma. Hum Gene Ther. 8:1997;349-358.
81. Qian C., Bilbao R., Bruna O., Prieto J. Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Hepatology. 22:1995;118-123.
82. Wildner O., Blaese R.M., Candotti F. Enzyme prodrug gene therapy: synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer. Cancer Res. 59:1999;5233-5238.
83. van der Eb M.M., Cramer S.J., Vergouwe Y., Schagen F.H., van Krieken J.H., van der Eb A.J., et al. Severe hepatic dysfunction after adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene and ganciclovir administration. Gene Ther. 5:1998;451-458.
84. Kaneko S., Hallenbeck P., Kotani T., Nakabayashi H., McGarrity G., Tamaoki T., et al. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res. 55:1995;5283-5287.
85. Qiao J., Doubrovin M., Sauter B.V., Huang Y., Guo Z.S., Balatoni J., et al. Tumor-specific transcriptional targeting of suicide gene therapy. Gene Ther. 9:2002;168-175.
86. Ohwada A., Hirschowitz E.A., Crystal R.G. Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver. Hum Gene Ther. 7:1996;1567-1576.
87. Hirschowitz E.A., Ohwada A., Pascal W.R., Russi T.J., Crystal R.G. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther. 6:1995;1055-1063.
88. Heise C., Sampson-Johannes A., Williams A., McCormick F., Von Hoff D.D., Kirn D.H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 3:1997;639-645.
89. Reilly R.T., Machiels J.P., Emens L.A., Jaffee E.M. Cytokine gene-modified cell-based cancer vaccines. Methods Mol Med. 69:2002;233-257.
90. Cao L., Kulmburg P., Veelken H., Mackensen A., Mezes B., Lindemann A., et al. Cytokine gene transfer in cancer therapy. Stem Cells. 16:(Suppl 1):1998;251-260.
91. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol. 70:1998;83-243.
92. Mazzolini G., Qian C., Narvaiza I., Barajas M., Borras-Cuesta F., Xie X., et al. Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level. Hum Gene Ther. 11:2000;113-125.
93. Leonard J.P., Sherman M.L., Fisher G.L., Buchanan L.J., Larsen G., Atkins M.B., et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 90:1997;2541-2548.
94. Barajas M., Mazzolini G., Genove G., Bilbao R., Narvaiza I., Schmitz V., et al. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology. 33:2001;52-61.
95. Mazzolini G., Narvaiza I., Bustos M., Duarte M., Tirapu I., Bilbao R., et al. Alpha(v)beta(3) integrin-mediated adenoviral transfer of interleukin-12 at the periphery of hepatic colon cancer metastases induces VCAM-1 expression and T-cell recruitment. Mol Ther. 3:2001;665-672.
96. Mazzolini G., Narvaiza I., Perez-Diez A., Rodriguez-Calvillo M., Qian C., Sangro B., et al. Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12. Gene Ther. 8:2001;259-267.
97. Narvaiza I., Mazzolini G., Barajas M., Duarte M., Zaratiegui M., Qian C., et al. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J Immunol. 164:2000;3112-3122.
98. Mazzolini G., Narvaiza I., Martinez-Cruz A., Arina A., Barajas M., Galofre J.C., et al. Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFNg-induced apoptosis. Gene Ther. 164:2003;1067-1078.
99. Melero I., Duarte M., Ruiz J., Sangro B., Galofre J., Mazzolini G., et al. Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas. Gene Ther. 6:1999;1779-1784.
100. Grimm C.F., Ortmann D., Mohr L., Michalak S., Krohne T.U., Meckel S., et al. Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice. Gastroenterology. 119:2000;1104-1112.
101. Woodberry T., Gardner J., Elliott S.L., Leyrer S., Purdie D.M., Chaplin P., et al. Prime boost vaccination strategies: CD8 T cell numbers, protection, and Th1 bias. J Immunol. 170:2003;2599-2604.
102. Rubin J., Galanis E., Pitot H.C., Richardson R.L., Burch P.A., Charboneau J.W., et al. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther. 4:1997;419-425.
103. Habib N.A., Ding S.F., el-Masry R., Mitry R.R., Honda K., Michail N.E., et al. Preliminary report: the short-term effects of direct p53 DNA injection in primary hepatocellular carcinomas. Cancer Detect Prev. 20:1996;103-107.
104. Horowitz J.A., Maneval D.C., Ryback M.E., Johnson D., Harris M.P., Demers W.G., et al. Intra-arterial p53 gene therapy of liver malignancies: preclinical studies and initial clinical observations. Cancer Gene Ther. 4:1997;S12.
105. Sung M.W., Yeh H.C., Thung S.N., Schwartz M.E., Mandeli J.P., Chen S.H., et al. Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. Mol Ther. 4:2001;182-191.
106. Habib N.A., Sarraf C.E., Mitry R.R., Havlik R., Nicholls J., Kelly M., et al. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther. 12:2001;219-226.
107. Habib N., Salama H., Abd El Latif Abu Median A., Isac Anis I., Abd Al Aziz R.A., Sarraf C., et al. Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther. 9:2002;254-259.
108. Reid T., Galanis E., Abbruzzese J., Sze D., Wein L.M., Andrews J., et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res. 62:2002;6070-6079.
109. Morse M.A., Deng Y., Coleman D., Hull S., Kitrell-Fisher E., Nair S., et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res. 5:1999;1331-1338.
110. Fong L., Hou Y., Rivas A., Benike C., Yuen A., Fisher G.A., et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A. 98:2001;8809-8814.
111. Sangro B., Qian C., Ruiz J., Prieto J. Tracing transgene expression in cancer gene therapy: a requirement for rational progress in the field. Mol Imaging Biol. 4:2002;27-33.
112. Bilbao R., Bustos M., Alzuguren P., Pajares M.J., Drozdzik M., Qian C., et al. A blood-tumor barrier limits gene transfer to experimental liver cancer: the effect of vasoactive compounds. Gene Ther. 7:2000;1824-1832.
113. Kondo M., Wagers A.J., Manz M.G., Prohaska S.S., Scherer D.C., Beilhack G.F., et al. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu Rev Immunol. 21:2003;759-806.
114. Deans R.J., Moseley A.B. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol. 28:2000;875-884.
115. Reyes M., Dudek A., Jahagirdar B., Koodie L., Marker P.H., Verfaillie C.M. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest. 109:2002;337-346.
116. Reyes M., Lund T., Lenvik T., Aguiar D., Koodie L., Verfaillie C.M. Purification and e vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood. 98:2001;2615-2625.
117. Moore M.A. Putting the neo into neoangiogenesis. J Clin Invest. 109:2002;313-315.